Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG6002 plus Flucytosine in colorectal cancer with liver metastases
NCT04194034Phase 2Terminated
- Sponsor
- Transgene SA
- Start
- Jan 2020
- Primary completion
- Feb 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
A Phase 2 trial of TG6002 in colorectal cancer (CRC), sponsored by Transgene SA. Started Jan 2020; status: terminated.
02
Drugs
TG6002
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04194034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04194034.